Table 2 Univariate analysis comparing clinical characteristics and outcomes of patients with Mycoplasma pneumoniae versus Streptococcus pneumoniae pneumonia
From: Severe atypical pneumonia in critically ill patients: a retrospective multicenter study
N (%) or median (IQR) | Total (N = 152) | Mycoplasma pneumoniae (N = 76) | Streptococcus pneumoniae (N = 76) | p value |
|---|---|---|---|---|
Demographics | ||||
Age | 55 [43–69] | 54 [41–69] | 57 [44–73] | 0.058 |
Female gender | 51 (34%) | 26 (34%) | 25 (33%) | 1 |
Comorbidities | ||||
Chronic respiratory disease | 36 (24%) | 22 (29%) | 14 (18%) | 0.18 |
Current smoker | 49 (41%) | 20 (38%) | 29 (43%) | |
Immunosuppression | 44 (29%) | 17 (22%) | 27 (36%) | 0.11 |
HIV infection | 14 (9%) | 2 (3%) | 12 (16%) | 0.009 |
Hematological malignancy | 18 (12%) | 9 (12%) | 9 (12%) | 1 |
Cancer | 12 (8%) | 4 (5%) | 8 (11%) | 0.37 |
Hypertension | 50 (33%) | 24 (32%) | 26 (34%) | 0.86 |
Reason for ICU admission | ||||
Acute respiratory distress | 140 (92%) | 70 (92%) | 70 (92%) | 0.59 |
Shock | 6 (4%) | 2 (3%) | 4 (5%) | |
Neurological symptoms | 4 (3%) | 2 (3%) | 2 (3%) | |
Other | 2 (1%) | 2 (3%) | 0 | |
Clinical respiratory findings | ||||
Respiratory rate | 31 [26–38] | 33 [27–38] | 30 [26–36] | 0.43 |
Signs of respiratory distress | 67 (47%) | 33 (49%) | 34 (45%) | 0.74 |
Rhonchi | 21 (16%) | 9 (15%) | 12 (16%) | 1 |
Crackles | 79 (59%) | 36 (61%) | 44 (59%) | 1 |
Signs of consolidation | 27 (21%) | 5 (9%) | 22 (30%) | 0.008 |
Decreased vesicular breath sounds | 38 (28%) | 10 (17%) | 28 (38%) | 0.007 |
Clinical presentation | ||||
Time since symptom onset (days) | 4 [2–7] | 6 [4–9] | 3 [2–7] | 0.0008 |
Fever | 112 (77%) | 58 (83%) | 54 (71%) | 0.12 |
Shock | 30 (20%) | 6 (8%) | 24 (32%) | 0.0004 |
Neurological symptoms | 21 (14%) | 1 (1%) | 20 (26%) | < 0.0001 |
Gastrointestinal symptoms | 16 (11%) | 1 (1%) | 15 (20%) | 0.0003 |
Extra-pulmonary signs | ||||
≥ 1 extra-pulmonary sign | 66 (43%) | 27 (36%) | 39 (51%) | 0.071 |
Arthritis | 1 (1%) | 1 (1%) | 0 | 1 |
Myocarditis | 4 (3%) | 4 (5%) | 0 | 0.12 |
Treatments in the ICU | ||||
Mechanical ventilation | 88 (58%) | 50 (66%) | 38 (50%) | 0.049 |
Duration of ventilation (days) | ||||
Discharged alive | 11 [7–19] | 13 [8–23] | 9 [6–16] | |
ICU death | 11 [3–18] | 18 [17–34] | 5 [2–15] | |
Vasopressors | 60 (39%) | 26 (34%) | 34 (45%) | 0.26 |
Renal replacement therapy | 17 (11%) | 7 (9%) | 10 (13%) | 0.49 |
SAPS II | 36 [24–47] | 32 [22–41] | 42 [30–55] | 0.0005 |
Outcomes | ||||
ICU stay length (days) | ||||
Discharged alive | 9 [5–19] | 15 [8–27] | 5 [3–10] | |
ICU death | 13 [4–27] | 37 [26–47] | 5 [3–14] | |
28-day mortality | 23 (15%) | 6 (8%) | 17 (22%) | 0.013 |